Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Hastarita Lawrenti
Departemen Medical PT. Kalbe Farma Tbk., Jakarta, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Perkembangan Terapi Kanker Prostat Hastarita Lawrenti
Cermin Dunia Kedokteran Vol 46, No 8 (2019): Kesehatan Anak
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i8.450

Abstract

Kanker prostat termasuk keganasan yang paling sering dijumpai pada pria. Five-year survival rate untuk kanker prostat sangat tinggi. Sekitar 25-33% kanker prostat lokal yang diterapi dengan pembedahan dan radioterapi akan rekuren. Kanker prostat stadium lanjut dikategorikan menjadi non-metastatik, metastatik, dan kanker prostat resisten kastrasi. Terapi penurunan hormon androgen dan kemoterapi masih penting untuk kanker prostat stadium lanjut. Enzalutamide dan terapi terkait penurunan androgen, penghambat CYP17 abiraterone, memperbaiki radiographic progression free survival (rPFS) dan menunda saat dimulainya kemoterapi.Prostate cancer is the most common malignancy in men. The overall 5-year survival rate for prostate cancer is very high. Approximately 25-33% of the patients with localized prostate cancer treated with surgery and radiotherapy will experience recurrence. Advanced prostate cancer is categorized into non-metastatic, metastatic, and castration-resistant prostate cancer (CRPC). Androgen deprivation therapy (ADT) and chemotherapy remain important for advanced prostate cancer. One of the ADTs, enzalutamide and treatment are related to androgen reduction, CYP17 inhibitor abiraterone, improve rPFS and delay time to initiation of chemotherapy
Perkembangan Terapi Kanker Prostat Hastarita Lawrenti
Cermin Dunia Kedokteran Vol. 46 No. 8 (2019): Pediatri
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i8.426

Abstract

Kanker prostat termasuk keganasan yang paling sering dijumpai pada pria. Five-year survival rate untuk kanker prostat sangat tinggi. Sekitar 25-33% kanker prostat lokal yang diterapi dengan pembedahan dan radioterapi akan rekuren. Kanker prostat stadium lanjut dikategorikan menjadi non-metastatik, metastatik, dan kanker prostat resisten kastrasi. Terapi penurunan hormon androgen dan kemoterapi masih penting untuk kanker prostat stadium lanjut. Enzalutamide dan terapi terkait penurunan androgen, penghambat CYP17 abiraterone, memperbaiki radiographic progression free survival (rPFS) dan menunda saat dimulainya kemoterapi. Prostate cancer is the most common malignancy in men. The overall 5-year survival rate for prostate cancer is very high. Approximately 25-33% of the patients with localized prostate cancer treated with surgery and radiotherapy will experience recurrence. Advanced prostate cancer is categorized into non-metastatic, metastatic, and castration-resistant prostate cancer (CRPC). Androgen deprivation therapy (ADT) and chemotherapy remain important for advanced prostate cancer. One of the ADTs, enzalutamide and treatment are related to androgen reduction, CYP17 inhibitor abiraterone, improve rPFS and delay time to initiation of chemotherapy.
Perkembangan Terapi Kanker Prostat Hastarita Lawrenti
Cermin Dunia Kedokteran Vol 46 No 8 (2019): Pediatri
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i8.426

Abstract

Kanker prostat termasuk keganasan yang paling sering dijumpai pada pria. Five-year survival rate untuk kanker prostat sangat tinggi. Sekitar 25-33% kanker prostat lokal yang diterapi dengan pembedahan dan radioterapi akan rekuren. Kanker prostat stadium lanjut dikategorikan menjadi non-metastatik, metastatik, dan kanker prostat resisten kastrasi. Terapi penurunan hormon androgen dan kemoterapi masih penting untuk kanker prostat stadium lanjut. Enzalutamide dan terapi terkait penurunan androgen, penghambat CYP17 abiraterone, memperbaiki radiographic progression free survival (rPFS) dan menunda saat dimulainya kemoterapi. Prostate cancer is the most common malignancy in men. The overall 5-year survival rate for prostate cancer is very high. Approximately 25-33% of the patients with localized prostate cancer treated with surgery and radiotherapy will experience recurrence. Advanced prostate cancer is categorized into non-metastatic, metastatic, and castration-resistant prostate cancer (CRPC). Androgen deprivation therapy (ADT) and chemotherapy remain important for advanced prostate cancer. One of the ADTs, enzalutamide and treatment are related to androgen reduction, CYP17 inhibitor abiraterone, improve rPFS and delay time to initiation of chemotherapy.
Co-Authors